1. Home
  2. NRT vs MXCT Comparison

NRT vs MXCT Comparison

Compare NRT & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRT

North European Oil Royality Trust

HOLD

Current Price

$7.99

Market Cap

76.7M

Sector

Energy

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$0.82

Market Cap

93.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRT
MXCT
Founded
1975
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.7M
93.0M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
NRT
MXCT
Price
$7.99
$0.82
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
79.5K
770.8K
Earning Date
05-29-2026
05-07-2026
Dividend Yield
9.65%
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
N/A
$33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.50
P/E Ratio
$39.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.36
$0.64
52 Week High
$10.49
$2.88

Technical Indicators

Market Signals
Indicator
NRT
MXCT
Relative Strength Index (RSI) 41.50 50.04
Support Level $7.51 $0.75
Resistance Level $9.52 $0.88
Average True Range (ATR) 0.41 0.05
MACD -0.03 0.00
Stochastic Oscillator 25.80 50.63

Price Performance

Historical Comparison
NRT
MXCT

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: